Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Therapeutic Targeting of Mitochondrial Superoxide in Hypertension

Therapeutic Targeting of Mitochondrial Superoxide in Hypertension Therapeutic Targeting of Mitochondrial Superoxide in Hypertension Anna E. Dikalova, Alfiya T. Bikineyeva, Klaudia Budzyn, Rafal R. Nazarewicz, Louise McCann, William Lewis, David G. Harrison, Sergey I. Dikalov Rationale: Superoxide (O ) has been implicated in the pathogenesis of many human diseases including hyperten- sion; however, commonly used antioxidants have proven ineffective in clinical trials. It is possible that these agents are not adequately delivered to the subcellular sites of superoxide production. Objective: Because the mitochondria are important sources of reactive oxygen species, we postulated that mitochondrial targeting of superoxide scavenging would have therapeutic benefit. Methods and Results: In this study, we found that the hormone angiotensin (Ang II) increased endothelial mitochondrial superoxide production. Treatment with the mitochondria-targeted antioxidant mitoTEMPO . . decreased mitochondrial O , inhibited the total cellular O , reduced cellular NADPH oxidase activity, and 2 2 restored the level of bioavailable NO. These effects were mimicked by overexpressing the mitochondrial MnSOD (SOD2), whereas SOD2 depletion with small interfering RNA increased both basal and Ang II–stimulated cellular O . Treatment of mice in vivo with mitoTEMPO attenuated hypertension when given at the onset of Ang II infusion and decreased blood pressure by 30 mm Hg following http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Research Wolters Kluwer Health

Therapeutic Targeting of Mitochondrial Superoxide in Hypertension

Circulation Research , Volume 107 (1) – Jul 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/therapeutic-targeting-of-mitochondrial-superoxide-in-hypertension-l6qZyQ6aCy

References (50)

ISSN
0009-7330
eISSN
1524-4571
DOI
10.1161/CIRCRESAHA.109.214601
pmid
20448215
Publisher site
See Article on Publisher Site

Abstract

Therapeutic Targeting of Mitochondrial Superoxide in Hypertension Anna E. Dikalova, Alfiya T. Bikineyeva, Klaudia Budzyn, Rafal R. Nazarewicz, Louise McCann, William Lewis, David G. Harrison, Sergey I. Dikalov Rationale: Superoxide (O ) has been implicated in the pathogenesis of many human diseases including hyperten- sion; however, commonly used antioxidants have proven ineffective in clinical trials. It is possible that these agents are not adequately delivered to the subcellular sites of superoxide production. Objective: Because the mitochondria are important sources of reactive oxygen species, we postulated that mitochondrial targeting of superoxide scavenging would have therapeutic benefit. Methods and Results: In this study, we found that the hormone angiotensin (Ang II) increased endothelial mitochondrial superoxide production. Treatment with the mitochondria-targeted antioxidant mitoTEMPO . . decreased mitochondrial O , inhibited the total cellular O , reduced cellular NADPH oxidase activity, and 2 2 restored the level of bioavailable NO. These effects were mimicked by overexpressing the mitochondrial MnSOD (SOD2), whereas SOD2 depletion with small interfering RNA increased both basal and Ang II–stimulated cellular O . Treatment of mice in vivo with mitoTEMPO attenuated hypertension when given at the onset of Ang II infusion and decreased blood pressure by 30 mm Hg following

Journal

Circulation ResearchWolters Kluwer Health

Published: Jul 1, 2010

There are no references for this article.